WO2008145839A1 - Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof - Google Patents

Abstract

The invention relates to the triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives of general formula (I) in which: A and X are, independently of one another, a nitrogen atom or a CH group; R1 is an NR3R4 group, in which R3 and R4 form, with the nitrogen atom which bears them, a heterocyclic group comprising 3 to 7 ring members that may incorporate an oxygen or sulphur atom, an NR group or an NR'-CO group, wherein said ring is optionally substituted with one or more groups selected from a halogen atom or a (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl or halo(C1- C6)alkoxy group, R2 is an aryl group, optionally substituted with one or more groups selected from a halogen atom or a methyl, trifluoromethyl, methoxy or trifluoromethoxy group. Process for the preparation thereof and therapeutic use thereof.

Description

 TRIAZOLOPYRIDINE CARBOXAMIDE AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

The present invention relates to triazolopyridine-carboxamide and triazolopyrimidine-carboxamide derivatives, to their preparation and to their therapeutic application.

The subject of the present invention is the compounds corresponding to formula (I)

(I) dans laquelle :

(I) in which:

A and X represent, independently of one another, a nitrogen atom or a CH group;

R ₁ represents a group NR ₃ R ₄ , in which R ₃ and R ₄ form, with the nitrogen atom which bears them, a heterocyclic group of 3 to 7 members capable of incorporating an oxygen or sulfur atom, an NR group or NR'-CO, said ring being optionally substituted with one or more groups selected from a halogen atom or a group

(C ₁ -C ₆ ) alkyl, (C ₁ -C ₆ ) alkoxy, halo (C ₁ -C ₆ ) alkyl, halo (C ₁ -C ₆ ) alkoxy,

R ₂ represents an aryl group, optionally substituted with one or more groups chosen from a halogen atom, a methyl, trifluoromethyl, methoxy or trifluoromethoxy group;

R represents a group chosen from a hydrogen atom, a (Cr C ₆ ) alkyl, (C ₃ -C ₇ ) cycloalkyl, (C ₃ -C ₇ ) cycloalkyl (CrC ₆ ) alkyl, C (O) R "group; , CO ₂ R ', SO ₂ R', CONR'R ", SO ₂ NR ¹ R", R 'and R "represent, independently of one another, one or more groups chosen from a hydrogen atom , a (C ₁ -C ₆ ) alkyl group, a (C ₃ -C ₇ ) cycloalkyl or (C ₃ -C ₇ ) cycloalkyl (C ₁ -C ₆ ) alkyl group.

The compounds of formula (I) may comprise one or more asymmetric carbon atoms. They can therefore exist as enantiomers or diastereoisomers. These enantiomers, diastereoisomers, as well as their mixtures, including the racemic mixtures, form part of the invention.

The compounds of formula (I) may exist in the form of bases or of addition salts with acids. Such addition salts are part of the invention.

These salts can be prepared with pharmaceutically acceptable acids, but the salts of other acids that are useful, for example, for the purification or the isolation of the compounds of formula (I) are also part of the invention.

The compounds of formula (I) may also exist in the form of hydrates or solvates, namely in the form of associations or combinations with one or more molecules of water or with a solvent. Such hydrates and solvates are also part of the invention.

In the context of the present invention, the following terms mean:

- C _t-2 , where t and z can take the values from 1 to 7, a chain or a carbon cycle may have from t to z carbon atoms, for example Ci- ₃ can characterize a carbon chain having from 1 to 3 carbon atoms;

a halogen atom: a fluorine, a chlorine, a bromine or an iodine;

an alkyl group: a saturated linear or branched aliphatic group. By way of examples, mention may be made of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, and the like; a cycloalkyl group: a saturated cyclic aliphatic group. By way of examples, mention may be made of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups, and the like;

a haloalkyl group: an alkyl group in which one or more hydrogen atoms have been substituted with a halogen atom; an alkoxy group: an -O-alkyl radical in which the alkyl group is as previously defined;

a haloalkoxy group: an alkoxy group in which one or more hydrogen atoms have been substituted with a halogen atom;

an aryl group: a cyclic aromatic group comprising between 6 and 14 carbon atoms. By way of examples of aryl group, mention may be made of phenyl or naphthyl;

a heterocyclic group: a saturated 5- to 7-membered cyclic group containing one to several heteroatoms such as nitrogen, oxygen or sulfur atoms. By way of examples, there may be mentioned pyrrolidinyl, piperidinyl, imidazolidine, pyrazolidine, dioxane, tetrahydropyranyl, piperidonyl, morpholinyl, piperazinyl, azetidine, azepine, thiomorpholinyl, N-methyl-piperazinyl, homopiperazine. the sulfur atoms may be present in the oxidized state (sulfoxide, sulfone).

In the different groups as defined below, the groups R ₁ and R ₂ , A and X, when they are not defined, have the same definitions as those mentioned above.

Among the compounds of formula (I) that are the subject of the invention, a first group of compounds consists of the compounds for which:

A represents a nitrogen atom, X represents a CH group.

Among the compounds of formula (I) that are the subject of the invention, a second group of compounds consists of the compounds for which:

A and X represent a CH group.

Among the compounds of formula (I) that are the subject of the invention, a third group of compounds consists of the compounds for which:

R ₁ represents a heterocyclic group, optionally substituted by one or more groups selected from a halogen atom or a haloalkyl group.

Among the compounds of formula (I) which are subjects of the invention, a fourth group of compounds is constituted by the compounds for which:

R 1 represents a morpholinyl, pyrrolidinyl or piperidinyl group, optionally substituted with one or more groups chosen from a halogen atom or a trifluoromethyl group.

The combinations of groups one to four above are also part of the invention.

Among the compounds of formula (I) that are subjects of the invention, mention may be made especially of the following compounds:

(5-Morpholin-4-yl- [1,2,3] triazolo [4,5-b] pyridin-3-yl) - [4- (3-trifluoromethyl-phenyl) -piperazin-1-yl] - methanone;

[4- (4-methoxy-phenyl) -piperazin-1-yl] - (5-pyrrolidin-1-yl [1,2,3] triazolo [4,5-b] pyridin-3-yl) methanone;

[5- (3,3-difluoro-pyrrolidin-1-yl) - [1,2,3] triazolo [4,5-b] pyridin-3-yl] - [4- (4-trifluoromethylphenyl)] - ) -piperazin-1-yl] -methanone; (5-Pyrroliciin-1-yl- [1,2,3] triazolo [4,5-b] pyridin-3-yl) - [4- (3-trifluoromethyl-phenyl) -piperazin-1-yl] - methanone;

(4-phenyl-piperidin-1-yl) - [5- (4-trifluoromethyl-piperidin-1-yl) - [1,2,3] triazolo [4,5-b] pyridin-3-yl] methanone.

In what follows, a protective group Pg is understood to mean a group that makes it possible, on the one hand, to protect a reactive function such as a hydroxyl or an amine during a synthesis and, on the other hand, to regenerate the intact reactive function. at the end of synthesis. Examples of protecting groups and methods of protection and deprotection are given in "Protective Groups in Organic Synthesis", Green et al., ^2nd Edition (John Wiley & Sons, Inc., New York), 1991.

By leaving group is meant, in what follows, a group that can be easily cleaved from a molecule by breaking a heterolytic bond, with departure from an electronic pair. This group can thus be easily replaced by another group during a substitution reaction, for example. Such leaving groups are, for example, halogens or an activated hydroxy group such as methanesulfonate, benzenesulfonate, p-toluenesulfonate, triflate, acetate, etc. Examples of leaving groups as well as references for their preparation are given in Advances in Organic Chemistry, J. March, 3 ^rd Edition, Wiley Interscience, 1985, p. 310-316.

According to the invention, the compounds of general formula (I) can be prepared according to the method of Scheme 1 which follows.

In a first step, the compounds of general formula (II), in which X is as defined above, are converted into compounds of general formula (III), in which X and R ₁ are as defined below. The conversion is carried out by an aminolysis reaction with an amine of general formula (IV) in which R ₃ and R ₄ are as defined above, in a solvent such as isopropanol or dimethylsulfoxide or a mixture of these. solvents, in the presence of a base such as potassium carbonate or diisopropylethylamine.

In a second step, the compounds of general formula (III), in which X and R 1 are as defined above, are converted into compounds of general formula (V), in which X, R ₁ , R ₂ and A are as defined above, by reaction with a carbamoyl chloride of general structure (VI). The reaction is carried out in a solvent such as N, N-dimethylformamide or N-methylpyrrolidone in the presence of a base such as sodium hydride or potassium ferf-butoxide or terf-pentoxide.

In a third step, the compounds of general formula (V) are converted into compounds of general formula (VII) in which X, R ₁ , R ₂ and A are as defined above, by reduction of a nitro group to an amino group. . The reaction can be carried out by various methods described in the literature or known to those skilled in the art, such as, for example, hydrogenation in the presence of a palladium, platinum or nickel-based catalyst and their variants.

Diagram 1

(H)

HNR ₃ R ₄ (IV)

(V) ^(V"⁾

(V) ^(V " ⁾

In the fourth step, the compounds of general formula (VII) are converted into compounds of general formula (I) by a diazotization-cyclization reaction. The reaction can be carried out using a nitrite, for example sodium or potassium nitrite in an acid medium or isoamyl or tert-butyl nitrite, in solvents such as water or tetrahydrofuran or their mixture.

The compounds of general formula (II) are commercially available. The amines of general formula (IV) and the carbamoyl chlorides of general formula (VI), if they are not commercially available, can be prepared by any method described in the literature or known to those skilled in the art.

The following examples illustrate the preparation of some compounds of the invention. These examples are not limiting and only illustrate the invention. Microanalyses, IR and NMR spectra and or LC-MS confirm the structures and purities of the compounds obtained. Melting points (PF) are given in degrees Celsius.

Example 1 (compound No. 2 of the table)

[4- (4-methoxy-phenyl) -piperazin-1-yl] - (5-pyrrolidin-1-yl) [1 _1, 2,3] triazolo [4,5-b] pyridin-3-yl) -methanone

1.1. 3-nitro-6-pyrrolidin-1-yl-pyridin-2-yl amine The suspension is heated at 60 ^° C. with stirring in a sealed tube for a period of 20 hours to a suspension of 1.735 g (10 mmol) of 2 ~ amino-6-chloro-3-nitro-pyridine, 1.66 mL (20 mmol) pyrrolidine and 1.66 mL (10 mmol) diisopropylethylamine in a mixture of 1 mL of dimethylsulfoxide and 5 mL of isopropanol. . It is cooled to ambient temperature and then diluted with 10 ml of isopropanol. The solid is collected by filtration and then washed with 2 × 5 ml of isopropanol. The solid is taken up in 20 ml of water. The suspension is stirred for 30 minutes. The solid is filtered off and then washed with 2x5 ml of water and 2x5 ml of ether and dried under vacuum in the presence of phosphorus pentoxide to obtain 1.91 g (9.17 mmol) of product in the form of intense yellow powder. 1H-NMR (DMSO-CZ ₆ , δ ppm): 8.15 (d, 1H), 7.95 (m, 2H), 6.15 (d, 1H), 3.60 (m,

4H), 2.00 (m, 4H).

1.2. 4- (4-Methoxy-phenyl) -piperazine-1-carboxylic acid, (3-nitro-6-pyrrolidin-1-yl-pyridin-2-yl) -amide Under Argon atmosphere, add 0, 25 g (6.25 mmol) of 60% sodium hydride in oil to a solution of 0.520 g (2.50 mmol) of 3-nitro-6-pyrrolidin-1-yl-pyridin-2-ylamine obtained in step 1.1. and 0.764 g (1.20 mmol) of 4- (4-methoxyphenyl) -1-piperazinecarbonyl chloride (prepared from 1- (4-methoxyphenyl) piperazine and triphosgene) in 8.5 mL of cooled dimethylformamide. by an ice bath. Stirring of the reaction mixture is continued at the temperature of the ice bath for 1 hour and then at room temperature for 2 hours. It is cooled with an ice bath and 50 ml of a 1M aqueous solution of chloride are added portionwise. ammonium then 20 mL of ethyl acetate. The mixture is stirred vigorously for 15 minutes. The solid is filtered and washed with 10 ml of ethyl acetate, 5 ml of water and 2x5 ml of ether. It is dried under vacuum in the presence of phosphorus pentoxide to obtain 0.79 g (1.85 mmol) of product in the form of an intense yellow powder. ¹H-NMR (DMSO-d ₆ , δ ppm): 8.15 (d, 1H), 6.95 (d, 2H), 6.85 (d, 2H), 6.25 (d, 1H) ,

3.70 (s, 3H), 3.65 (m, 4H), 3.55 (m, 4H), 3.05 (m, 4H), 1.95 (m, 4H).

1.3. [4- (4-Methoxy-phenyl) -piperazin-1-yl] - (5-pyrrolidin-1-yl) [1,2,3] triazolo [4,5-b] pyridin-3-yl) -methanone 0.730 g (1.71 mmol) of 4- (4-methoxy-phenyl) -piperazine-1-carboxylic acid, (3-nitro-6-pyrrolidin-1-yl-pyridin-2-yl) -amide obtained in step 1.2., in a mixture of 68 mL of methanol and 1.0 mL of a 5N solution of hydrochloric acid (5.14 mmol) in isopropanol. 0.333 g of platinum (0.17 mmol) at 10% on charcoal is added. The mixture is stirred under a hydrogen atmosphere at 30 psi (2 bar) for 2.5 hours. The mixture is filtered and the filtrate is evaporated to obtain 0.97 g of product in the form of a violet solid foam, which is used as it is in the next step.

1.4 The solid is suspended in 8.5 ml of tetrahydrofuran and then 0.30 ml (2.21 mmol) of isoamyl nitrite and 0.694 g (5.10 mmol) of sodium acetate trihydrate are added. The mixture is stirred for 18 hours at room temperature. 50 ml of ethyl acetate and 25 ml of a 0.5M aqueous solution of potassium carbonate are added. The organic phase is decanted and washed with 25 ml of an aqueous solution

0.5M potassium carbonate and then 25 mL of water and 25 mL of a saturated aqueous solution of sodium chloride. It is dried over sodium sulphate and evaporated to dryness. The product is purified by chromatography on silica gel, eluting with a 40:60 mixture and then 50:50 and 60:40 of ethyl acetate and cyclohexane. The product obtained is purified by chromatography on silica gel, eluting with a 95: 5 mixture and then 90:10, 85:15 and

80:20 dichloromethane and ethyl acetate. The product is recrystallized from isopropanol to give 0.175 g (0.43 mmol) of product as pinkish crystals.

Melting point ( ⁰ C): 138-140 LC-MS (m / z): 408 (MH +), 380 (MH + -N ₂ ) IR (KBr ₁ cm ^-1 ): 1704, 1612 1H-NMR (CDCl ₃ δ ppm): 8.05 (d, 1H), 6.95 (d, 2H), 6.90 (d, 2H), 6.55 (d, 1H),

4.05 (m, 2H), 3.80 (m + s, 5H), 3.60 (m, 4H), 3.25 (m, 4H), 2.05 (m, 4H). Table 1 which follows illustrates the chemical structures and the physical properties of some examples of compounds according to the invention. In this table :

in the "salt" column, "-" represents a compound in free base form, while "HCl" represents a compound in the hydrochloride form; Ph represents a phenyl group.

PF represents the melting point of the compounds in degrees Celsius.

Table 1

(I)

The compounds according to the invention surprisingly exhibit an inhibitory effect on the MGL enzyme (monoacyl glycerol lipase). The MGL enzyme catalyzes the hydrolysis of endogenous derivatives of monoglyceride esters of different fatty acids (FEBS Letters 1998, 429, 152-156) and in particular the hydrolysis of 2-arachidonoylglycerol (2-AG) and 1 (3 arachidonoylglycerol (1 (3) -AG) (J. Biol Chem 1987, 272 (48), 27218-27223, Proc Natl Acad Sci USA 2002, 99 (16), 10819-10824; Pharmacol 2004, 67, 1381- 1387, Mol Pharmacol 2004, 66 (5), 1260-1264). The 2-AG and 1- (3) -AG derivatives in particular interact with the cannabinoid receptors (J. Biol Chem 1999, 274 (5), 2794-2801, J. Biol Chem 2000, 275 (1)). 605-612, British J. Pharmacol 2001, 134, 664-672).

The compounds of the invention block this degradation pathway and increase the tissue levels of these derivatives and in particular 2-AG and / or 1 (3) -AG. As such, they can be used in the prevention and treatment of pathologies in which 2-AG and / or 1 (3) -AG in particular and / or any other substrate metabolized by the MGL enzyme are involved (Progress Lipid Research 2006, 45, 405-446).

The compounds according to the invention may also have an additional inhibitory effect on the enzyme FAAH (Fatty Acid Amide Hydrolase). The enzyme FAAH (Chemistry and Physics of Lipids, (2000), 108, 107-121) catalyzes the hydrolysis of endogenous derivatives of amides and esters of different fatty acids such as Λ / -arachidonoylethanolamine (anandamide), W-palmitoylethanolamine, N-oleoylethanolamine or oleamide. These derivatives exert different pharmacological activities by interacting, inter alia, with the cannabinoid and vanilloid receptors.

The compounds of the invention block this pathway of degradation and increase the tissue level of these endogenous substances. They can be used as such in the prevention and treatment of pathologies in which the endogenous cannabinoids and / or any other substrate metabolized by the enzyme FAAH, are involved.

Trials consisted of measuring the in vitro activity of the compounds of the invention on the MGL enzyme.

Inhibitory activity was measured in a radioenzyme assay based on the measurement of the hydrolysis product of 2-Oleoyl Glycerol ([ ³ H] 2-OG) by MGL. The hydrolysis products of [ ³ H] 2-OG, labeled on glycerol, are oleic acid and [ ³ H] glycerol and the MGL enzyme source is a mouse brain homogenate where the cerebellum and the spinal bulb have been eliminated. The mouse brains are removed, stored at -80 ^° C. until use or homogenized immediately 2 times 5 seconds using the Precellys device at 5000 rpm (Bertin) in a 10 mM Tris-HCl buffer, NaCl 15mM, 1mM EDTA (pH8) at 4 ° C. The concentration of the homogenates is then adjusted to 7.5 μg / μL.

The dilution range of the compounds is made from stock solutions at 20 mM in 100% DMSO. The first dilution of this range is carried out in 100% DMSO then the second in the enzyme reaction buffer (50 mM phosphate, 0.1% BSA) resulting in the achievement of a concentration range 10 times concentrated. The test compounds are preincubated at the selected concentration for 20 minutes with the mouse brain homogenate preparation. The final concentration of DMSO in the enzymatic reaction does not exceed 0.1%.

The assay of the MGL activity is carried out in a 96-well microplate in a final reaction volume of 100 μl. Briefly, 75 μg of protein, preincubated with the test compounds, are diluted in 50 mM phosphate buffer containing 0.1% BSA and incubated for 20 minutes at room temperature in the presence of 50 μM of 2-OG containing a quantity of [ ³ H] 2-OG of 0.027 μCi / well (specific activity of 20 Ci / mmol). The reaction is stopped and the products formed are separated by the addition and the mixture of 100 μl of chloroform / methanol (1/1). After stirring for 10 minutes, the microplate is centrifuged for 15 minutes at 4000 g and an aliquot of 30 μl of the aqueous phase containing the [ ³ H] glycerol product is removed and then counted for 5 minutes by liquid scintillation (Wallac 1450 Microbeta).

Inhibitory activity against MGL is given by the concentration which inhibits 50% of MGL activity. Under these conditions, the most active compounds of the invention have a Cl ₅₀ (concentration inhibiting 50% MGL control enzyme activity) of between 0.001 and 0.1 μM. For example, compound No. 1 showed a Cl ₅₀ of 0.004 μM.

Trials consisted in measuring the in vitro activity of the compounds of the invention on the enzyme FAAH.

Inhibitory activity was measured in a radioenzymatic assay based on the measurement of the hydrolysis product (ethanolamine [1-3H]) of anandamide by FAAH (Life Science (1995), 56, 1999-2005 and Journal of Pharmacology and Experimented Therapeutics (1997), 283, 729-734). The hydrolysis products of ethanolamine-labeled T [ ³ H] anandamide are arachidonic acid and T [ ³ H] ethanolamine and the enzyme source FAAH is a mouse brain homogenate where the cerebellum and the spinal bulb have been eliminated. The brains of mice are removed, stored at -80 ^° C. until use or homogenized immediately 2 times 5 seconds using the Precellys apparatus at 5000 rpm (Bertin) in 10 mM Tris-HCl buffer, NaCl 15 mM, 1 mM EDTA (pH8) at ^{40 °} C. The concentration of the homogenates is then adjusted to a concentration of 20 μg / μL.

The dilution range of the compounds is made from stock solutions at 20 mM in 100% DMSO. The first dilution of this range is carried out in 100% DMSO then the second in the enzyme reaction buffer (10 mM Tris-HCl, 15 mM NaCl, 1 mM EDTA (pH 8), 0.1% BSA) resulting in the production of a concentration range 10 times concentrated. The test compounds are preincubated at the selected concentration for 20 minutes with the mouse brain homogenate preparation. The final concentration of DMSO in the enzymatic reaction does not exceed 0.1%.

The assay of the FAAH activity is carried out in 96-well microplate in a final reaction volume of 70 μL. Briefly, 200 μg of brain homogenate mice, preincubated with the compounds to be tested, are diluted in 10 mM Tris-HCl, 15 mM NaCl, 1 mM EDTA (pH 8) containing 0.1% BSA and incubated for 20 minutes at room temperature, in the presence of 10 μM of anandamide containing an amount of [ ³ H] -anandamide of 0.01 μCi / well (specific activity of 60 Ci / mmol). The reaction is stopped and the products formed are separated by the addition and the mixture of 140 μl of chloroform / methanol (2/1). After stirring for 10 minutes, the microplate is centrifuged for 15 minutes at 4000 g and an aliquot of 30 μl of the aqueous phase containing the [ ³ H] ethanolamine product is removed and then counted for 5 minutes by liquid scintillation (Wallac 1450 Microbeta). .

Under these conditions, the most active compounds of the invention have a CUo (50% concentration inhibiting the enzymatic activity controlling FAAH) of between 0.001 and 0.1 μM. For example, compound No. 1 showed a Cl ₅₀ of 0.01 μM.

It thus appears that the compounds according to the invention have a selective inhibitory activity with respect to MGL or mixed with respect to MGL and FAAH.

The compounds according to the invention can therefore be used for the preparation of medicaments, in particular drugs which inhibit the MGL enzyme or the MGL and FAAH enzymes.

Thus, according to another of its aspects, the subject of the invention is medicaments which comprise a compound of formula (I), or an addition salt thereof to a pharmaceutically acceptable acid, or a hydrate or a solvate of compound of formula (I).

These drugs find their therapeutic use, particularly in the treatment and prevention of: pain including acute or chronic pain of neurogenic type: migraine, neuropathic pain including forms associated with the herpes virus and diabetes; acute or chronic pain associated with inflammatory diseases: arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease, irritable bowel syndrome; acute or chronic peripheral pain; dizziness, vomiting, nausea, especially those resulting from chemotherapy; eating disorders, particularly anorexia and cachexia of various natures; metabolic syndrome and its manifestations, including obesity; dyslipidemia and its manifestations, including atherosclerosis and coronary heart disease; neurological and psychiatric pathologies: tremor, dyskinesia, dystonia, spasticity, compulsive and obsessive behavior, Tourette's syndrome, all forms of depression and anxiety of all kinds and origins, mood disorders, psychoses; acute and chronic neuro-degenerative diseases: Parkinson's disease, Alzheimer's disease, senile dementia, Huntington's chorea, lesions related to cerebral ischemia and cranial and medullary traumas, amyotrophic lateral sclerosis; epilepsy; sleep disorders including sleep apnea; cardiovascular diseases especially hypertension, cardiac arrhythmias, arteriosclerosis, heart attack, ischemic heart disease; renal ischemia; cancers: benign tumors of the skin, papillomas and brain tumors, prostate tumors, brain tumors (glioblastomas, medullo-epitheliomas, medulloblastomas, neuroblastomas, embryonic origin tumors, astrocytomas, astroblastomas, ependyomas, oligodendrogliomas, plexus tumors, neuroepitheliomas, epiphysis tumor, ependymoblastomas, malignant meningiomas, sarcomatoses, malignant melanomas, schwénnomes); disorders of the immune system, including autoimmune diseases: psoriasis, lupus erythematosus, connective tissue diseases or connective tissue diseases, Sjögren's syndrome, ankylosing spondylitis, undifferentiated spondyloarthritis,

Behcet's, hemolytic autoimmune anemias, multiple sclerosis, amyotrophic lateral sclerosis, amyloidosis, transplant rejection, diseases affecting the plasma cell line; allergic diseases: immediate or delayed hypersensitivity, allergic rhinitis or conjunctivitis, contact dermatitis; parasitic, viral or bacterial infectious diseases: AIDS, meningitis; inflammatory diseases, including joint diseases: arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease, irritable bowel syndrome; osteoporosis; eye conditions: ocular hypertension, glaucoma; lung diseases: diseases of the respiratory tract, bronchospasm, cough, asthma, chronic bronchitis, chronic obstruction of the respiratory tract, emphysema; gastrointestinal diseases: irritable bowel syndrome, inflammatory bowel disorders, ulcers, diarrhea; urinary incontinence and bladder inflammation.

According to another of its aspects, the present invention relates to pharmaceutical compositions comprising, as active principle, a compound according to the invention. These pharmaceutical compositions contain an effective dose of at least one compound according to the invention, or a pharmaceutically acceptable salt, a hydrate or solvate of said compound, as well as at least one pharmaceutically acceptable excipient. Said excipients are chosen according to the pharmaceutical form and the desired mode of administration, from the usual excipients which are known to those skilled in the art.

In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, the active ingredient of formula (I) above, or its salt, solvate or hydrate may be administered in unit dosage form, in admixture with conventional pharmaceutical excipients, to animals and humans for the prophylaxis or treatment of the above disorders or diseases.

Suitable unit dosage forms include oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual, oral, intratracheal, intraocular, intranasal forms of administration. by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms and implants. For topical application, the compounds according to the invention can be used in creams, gels, ointments or lotions.

By way of example, a unitary form of administration of a compound according to the invention in tablet form may comprise the following components: Compound according to the invention 50.0 mg

Mannitol 223.75 mg

Croscarmellose sodium 6.0 mg

Corn starch 15.0 mg Hydroxypropyl methylcellulose 2.25 mg

Magnesium stearate 3.0 mg

The present invention, according to another of its aspects, also relates to a method of treatment of the pathologies indicated above which comprises the administration to a patient of an effective dose of a compound according to the invention, or one of its pharmaceutically acceptable salts or hydrates or solvates.

Claims

1. Compound corresponding to formula (I)

(I) in which : A and X represent, independently of one another, a nitrogen atom or a CH group; R ₁ represents a group NR ₃ R ₄ , in which R ₃ and R ₄ form, with the nitrogen atom which bears them, a heterocyclic group of 3 to 7 members capable of incorporating an oxygen or sulfur atom, an NR group or NR'-CO, said ring being optionally substituted with one or more groups selected from a halogen atom or a group (C ₁ -C ₆ ) alkyl, (C ₁ -C ₆ ) alkoxy, halo (C ₁ -C ₆ ) alkyl, halo (C ₁ -C ₆ ) alkoxy, R ₂ represents an aryl group, optionally substituted with one or more groups chosen from a halogen atom, a methyl, trifluoromethyl, methoxy or trifluoromethoxy group; R represents a group chosen from a hydrogen atom, a (C ₁ -C ₆ ) alkyl, (C ₃ -C ₇ ) cycloalkyl, (C ₃ -C ₇ ) cycloalkyl (C ₁ -C ₆ ) alkyl, C (O) group; R ', CO ₂ R', SO ₂ R ', CONR'R ", SO ₂ NR ¹ R", R' and R "represent, independently of one another, one or more groups selected from a d hydrogen, a (C ₁ -C ₆₎ alkyl, (C ₃ - C ₇₎ cycloalkyl or (C ₃ -C ₇₎ cycloalkyl (CrC ₆₎ alkyl, in the form of base or of salt of addition to an acid, as well as to the hydrate or solvate state. 2. Compound of formula (I) according to claim 1, characterized in that A represents a nitrogen atom, X is a CH, base or acid addition salt, hydrate or solvate state. 3. Compound of formula (I) according to one of claims 1 or 2, characterized in that A and X are CH, base or acid addition salt, and hydrate or solvate. 4. Compound of formula (I) according to one of claims 1 to 3, characterized in that R ₁ represents a heterocyclic group, optionally substituted with one or more groups selected from a halogen atom or a haloalkyl group, at base state or addition salt with an acid, as well as with the hydrate or solvate state. 5. Compound of formula (I) according to one of claims 1 to 4, characterized in that R ₁ represents a morpholinyl, pyrrolidinyl or piperidinyl group, optionally substituted by one or more groups chosen from a halogen atom or a trifluoromethyl group, in the form of a base or of an addition salt with an acid, as well as the state of hydrate or solvate. 6. Compound of formula (I) according to one of claims 1 to 5, characterized in that it is chosen from: (5-Morpholin-4-yl- [1,2,3] triazolo [4,5-b] pyridin-3-yl) - [4- (3-trifluoromethyl-phenyl) piperazin-1-yl] - methanone - [4- (4-methoxy-phenyl) -piperazin-1-yl] - (5-pyrrolidin-1-yl [1,2,3] triazolo [4,5-b] pyridin-3-yl) - methanone [5- (3,3-difluoropyrrolidin-1-yl) - [1,2,3] triazolo [4,5-b] pyridin-3-yl] - [4- (4-trifluoromethylphenyl)] piperazin-1 ~ YLJ-methanone (5-pyrrolidin-1-yl- [1,2,3] triazolo [4,5-b] pyridin-3-yl) - [4- (3-trifluoromethyl-phenyl) -piperazin-1-yl] - methanone (4-phenyl-piperidin-1-yl) - [5- (4-trifluoromethyl-piperidin-1-yl) - [1,2,3] triazolo [4,5-b] pyridin-3-yl] methanone. 7. Process for the preparation of a compound of formula (I) according to any one of claims 1 to 6, characterized in that one converts a compound of general formula (VII)

(VII) wherein R ₁ , R ₂ , X and A are as defined in formula (I) according to claim 1, in compound of general formula (I) by a diazotization-cyclization reaction, under the action of a nitrite. 8. Medicament, characterized in that it comprises a compound of formula (I) according to any one of claims 1 to 6, or a salt of addition of this compound to a pharmaceutically acceptable acid, or a hydrate or a solvate of the compound of formula (I). 9. Pharmaceutical composition, characterized in that it comprises a compound of formula (I) according to any one of claims 1 to 6, or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, and at least a pharmaceutically acceptable excipient. 10. Use of a compound of formula (I) according to any one of claims 1 to 6 for the preparation of a medicament for the treatment and prevention of a pathology in which 2-arachidonoylglycerol (2-AG ) and endogenous 1 (3) - arachidonoylglycerol and / or any other substrate metabolized by the MGL enzyme are involved. 11. Use of a compound of formula (I) according to any one of claims 1 to 6 for the preparation of a medicament for the treatment and prevention of a pathology in which the endogenous anandamide and / or any other substrate metabolized by the enzyme FAAH are involved. 12. Use of a compound of formula (I) according to any one of claims 1 to 6, in the form of base, hydrate or solvate pharmaceutically acceptable, for the preparation of a medicament for preventing or to treat acute or chronic pain, dizziness, vomiting, nausea, eating disorders, metabolic syndrome, dyslipidemia, neurological and psychiatric pathologies, acute or chronic neuro-degenerative diseases, epilepsy, sleep disorders, cardiovascular diseases, renal ischemia, cancers, immune system disorders, allergic diseases, parasitic, viral or bacterial infectious diseases, inflammatory diseases, osteoporosis, eye diseases, lung diseases , gastrointestinal diseases, urinary incontinence, bladder inflammation. 13. Compound of formula (I) according to any one of claims 1 to 6, the basic state, hydrate or solvate pharmaceutically acceptable for the prevention or treatment of acute or chronic pain, dizziness, vomiting, nausea, eating disorders, metabolic syndrome, dyslipidemias, neurological and psychiatric pathologies, acute or chronic neuro-degenerative diseases, epilepsy, sleep disorders, cardiovascular diseases, renal ischemia, cancers, disorders of the immune system, allergic diseases, parasitic infectious diseases, viral or bacterial, inflammatory diseases, osteoporosis, ocular affections, pulmonary diseases, gastrointestinal diseases, urinary incontinence, bladder inflammation.